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Schistosomiasis is a major public health problem in Africa. However, it is only recently that its burden has become recognised as a
significant component impacting on the health and development of preschool-aged children. A longitudinal study was conducted
in Zimbabwean children to determine the effect of single praziquantel treatment on Schistosoma haematobium-related morbidity
markers: microhaematuria, proteinuria, and albuminuria. Changes in these indicators were compared in 1–5 years versus 6–10
years age groups to determine if treatment outcomes differed by age. Praziquantel was efficacious at reducing infection 12 weeks
after treatment: cure rate = 94.6% (95% CI: 87.9–97.7%). Infection rates remained lower at 12 months after treatment compared to
baseline in both age groups. Among treated children, the odds ofmorbidity at 12weekswere significantly lower compared to baseline
for proteinuria: odds ratio (OR) = 0.54 (95% CI: 0.31–0.95) and albuminuria: OR = 0.05 (95% CI: 0.02–0.14). Microhaematuria
significantly reduced 12 months after treatment, and the effect of treatment did not differ by age group: OR = 0.97 (95% CI: 0.50–
1.87). In conclusion, praziquantel treatment has health benefits in preschool-aged children exposed to S. haematobium and its
efficacy on infection and morbidity is not age-dependent.
1. Introduction
Urogenital schistosomiasis, caused by the waterborne para-
sitic helminth Schistosoma haematobium, is an important but
neglected tropical disease in Africa [1–3]. The disease causes
significant paediatric health problems in endemic regions,
with negative impacts on child health and development. In S.
haematobium infections, damage caused by the parasite eggs
lodged in tissues or exiting the body via the urine can result
in bladder or urinary tract pathology, often characterized by
blood in urine (macro- or microhaematuria), painful urina-
tion (dysuria), and proteinuria [4, 5]. High levels of albumin
in urine have also been shown to be strongly correlated with
urinary tract pathology due to S. haematobium infection [6].
Chronic infection with schistosomes in children is associated
with complications such as anaemia, malnutrition, growth
retardation, reduced physical fitness, and impaired memory
and cognition [7, 8]. Infection and morbidity are controlled
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by treatment of infected individuals with the antihelminthic
drug, praziquantel (PZQ) [9, 10]. Delay or a lack of inter-
vention can result in more severe and irreversible forms
of morbidity including urinary bladder cancer (squamous
cell carcinoma) and chronic kidney disease, which may
eventually result in death [11–13].
In several countries implementing schistosomiasis con-
trol programmes, the control strategies follow the directive
by the World Health Assembly resolutions (WHA 54.19 and
WHA 65.21) in 2001 [9], involving regular school based
deworming using PZQ, aimed at reducingmorbidity and pro-
moting child health. However, a growing number of studies
from Africa have shown that preschool children (aged ≤5
years) are also at high risk of schistosomiasis through passive
exposure to infection whilst being bathed with infested water
[14–18]. Furthermore, recent studies have also shown that
PZQ treatment of schistosome infection is safe in preschool
children [16, 19]. These findings have led to a new major
recommendation by the World Health Organization (WHO)
in 2010, stating that preschool-aged children should be
considered for treatment through the regular health services
and in ongoing public health intervention programmes [20].
This recent development in schistosomiasis control policy has
heightened the need for a clear understanding on the health
benefits of PZQ beyond the immediate reduction in infection
levels in preschool-aged children in order to improve the
effectiveness of interventions targeting this age group [21].
In a previous study in this population, we showed that,
based on attributable fractions, albuminuria measured as
the urine albumin-to-creatinine ratio (UACR) was the most
reliable tool for detecting schistosome-related morbidity,
followed by proteinuria and microhaematuria determined by
dipsticks, visual urine inspection, questionnaires, and lastly
clinical examination [22]. Thus, in this current study we
focused on albuminuria, proteinuria, and microhaematuria.
The aim of this study was to evaluate the immediate health
benefits of PZQ in preschool-aged (1–5 years) children
endemically exposed to S. haematobium at 12-week posttreat-
ment and to determine if a single dose of PZQ (40mg/kg) has
sustainable impact on the health status of these children by
assessing changes in infection rates and levels of schistosome-
related morbidity markers (microhaematuria, proteinuria,
and albuminuria) 12 months after treatment. Furthermore,
we sought to determinewhether the impact of PZQ treatment
outcome is age-dependent by comparing these indicators in
preschool and primary school-aged (6–10 years) children
in the same population. The findings of our present study
provide an operational recommendation for future studies on
the control of paediatric schistosomiasis, whilst also giving
further insights into the health benefits of antihelminthic
treatment in preschool-aged children.
2. Materials and Methods
2.1. Ethics Statement and Consent. Prior to commencing
the study, ethical clearance was obtained from the Med-
ical Research Council of Zimbabwe (Approval Reference
MRCZ/A/1615). In addition, the study received institutional
approval from the University of Zimbabwe. Permission to
conduct the study was obtained from the Provincial Medical
Director, the District Educational Officer, and heads of
schools in the study area. Study objectives and procedures
were fully explained to the community, parents/guardians,
teachers, and primary school-aged children in the local
language, Shona. Samples were collected only after obtaining
informed written parental consent and study participants’
oral assent. Participants were permitted to withdraw from the
study at any point without further obligation.
2.2. Study Site. The studywas undertaken inMurewa district,
in the northeast of Zimbabwe (31∘90󸀠E; 17∘63󸀠S) where S.
haematobium is endemic.The area has low transmission of S.
mansoni and soil transmitted helminths (STH) as previously
reported in other studies [23, 24]. In a nationwide survey
among school-aged children in 2010 in Zimbabwe, Midzi
et al. [25] reported a schistosomiasis prevalence of 31.2% in
Murewa district based on parasitological diagnosticmethods.
To confirm this reported level of schistosome infection in
the community in our study site, we initially conducted a
pilot study among primary school-going children (aged 6–
10 years) as per sampling guidelines and recommendations
by the WHO [26, 27]. A random sample of 50 compliant
children from the two schools in the study area (25 from
each school) was screened for schistosome infections by
parasitology. Children found positive for infection during the
pilot survey were treated with the recommended single dose
of PZQ (40mg/kg) but were then ineligible for participation
in the main study.
2.3. Study Design and Population. The longitudinal study
was designed to relate changes in the levels of infection and
markers of schistosome-related morbidity to the two age
groups of children (1–5 years versus 6–10 years) conducted
over a period of 12months.There were two aspects to the lon-
gitudinal study design investigating (i) the short term effects
of PZQ treatment which measured the morbidity markers
and infection levels before treatment/baseline (February–
March 2012) and 12 weeks (May 2012) after treatment, the
workflow for this aspect of the study shown in Figure 1(a), and
(ii) the longer-term effects of PZQ treatment whichmeasured
the morbidity markers and infection levels before treatment
and 12 months (March 2013) after treatment; the workflow
for this aspect of the study is shown in Figure 1(b). The 388
children who received treatment at baseline (Figures 1(a) and
1(b)) participated in both aspects of the study, so that the 303
children whose infection status was confirmed egg-negative
at the 12-week efficacy check survey formed the treated cohort
for follow-up at 12 months (Figure 1(b)). Untreated children
(Figure 1(a)) were not followed up beyond 12 weeks. Children
were recruited from two primary schools (typically for 6–
10 years ages) and the early childhood development centres
(ECDs) for preschool-aged children located within each of
the primary schools. The schools also served as recruitment
centres for children aged between 1 and 5 years not enrolled
in any of the educational programmes in the study area
who were also invited for enrolment to participate in this
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Figure 1: (a) Study design flowchart showing the number of children included for the final analysis to assess the effect of praziquantel
treatment efficacy 12 weeks after treatment. Participants who preferred not to receive treatment but voluntarily remained in the study at
12 weeks were utilized as untreated controls. (b) Study design flowchart to assess the effect of praziquantel 12 months after treatment.
study. The villages within the study sites share the same
river systems; therefore the transmission dynamics in the two
schools (and associated ECDs) were similar.
2.4. Screening and Follow-UpCriteria. In order to be included
in this study at baseline, children had to meet the following
criteria: (i) they had been life-long (i.e., permanent) resi-
dents of the study area, (ii) they had no prior history of
antihelminthic treatment (assessed by questionnaires admin-
istered to parents/guardians of all children), and (iii) they had
provided at least two urine samples collected on consecutive
days for the parasitological diagnosis of S. haematobium
infection. For potential exclusion, children were assessed
to identify (i) preexisting medical conditions or clinical
symptoms of tuberculosis, any form of fever, or other signs of
being unwell upon examination by study clinicians, (ii) recent
major operation or illness as reported by parents/guardians,
and (iii) infection with any of STHs or S. mansoni. No soil
transmitted helminth infections were detected in this study
cohort and 27 children positive for S. mansoni were offered
PZQ treated but excluded based on this criterion. Participat-
ing children that were found egg-positive for S. haematobium
at the 12-week efficacy check were treated with 40mg/kg
praziquantel but excluded from further follow-up to ensure
that, in addition to new infections, only “true” reinfection
was measured. Children who met the eligibility criteria,
with informed consent, but would not accept treatment on
religious grounds, or were absent on treatment survey days
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but voluntarily remained in our study cohort at 12 weeks
effectively became untreated controls for evaluating the effect
of treatment on schistosome-related morbidity markers. At
the end of the study (12 months), PZQ treatment was offered
to all children diagnosed egg-positive for infection.
2.5. Parasitological Methods. At all survey time points, urine
sampleswere collected on three consecutive days for parasito-
logical examinations. S. haematobium infection was detected
by microscopic examination of the parasite eggs in urine,
processed using the standard urine filtrationmethod [28]. For
each child, infection intensity was expressed as the arithmetic
mean of egg counts per 10mL urine of samples collected on
consecutive days. At least two stool samples were also col-
lected over three consecutive days, processed using the Kato-
Katzmethod [29], and subsequently examined bymicroscopy
for the diagnosis of S. mansoni. In a previous study we also
determined the infection status of the children by serology;
details of this methodology are described elsewhere [30].
2.6. Assessment ofMorbidityMarkers. Threeurinarymarkers,
microhaematuria, proteinuria, and albuminuria identified in
our earlier published study [22], were chosen for investigating
the effect of PZQ treatment on schistosome-relatedmorbidity
in this present study. Urine samples collected between 10:00 h
and 14:00 h and processed on the first day of each survey time
point were examined for microhaematuria and proteinuria,
detected by dipstick reagent strip test (Uripath, Plasmatec,
UK). Briefly, the reagent end of the test strip was dipped into
fresh, well-mixed urine for 40 seconds. Upon removal, the
test areawas comparedwith a standard colour chart following
the manufacturer’s guidelines and the dipstick test results
were calibrated as either positive or negative. To assess the
stability of dipstick urinalysis [31], repeated tests (at least two
repetitions) were performed on a random sample (𝑛 = 189)
of urine specimens, allowing for time delay of up to 5minutes
between each of the repeated readings.There were nomarked
differences observed between repeated tests to suggest poten-
tial instabilities of urinalysis due to delays in dipstick testing.
No observer bias was suggested by the urinalysis results
when comparing the visually recorded dipstick readings to
those read automatically using Siemens’ CLINITEK Status
+ Analyzer (Bayer, UK). CLINITEK Microalbumin Reagent
Strips (Bayer, UK)were used to determine the urine albumin-
to-creatinine ratio (UACR) threshold levels (normal: UACR
< 3.4mg/mmol, abnormal: UACR ≥ 3.4mg/mmol, or highly
abnormal: UACR ≥ 33.9mg/mmol), as read from the instru-
ment following the manufacturer’s guidelines. For each child,
albuminuria as a marker of schistosome-related morbidity
associated with urinary tract pathology was defined as a
positive test for high abnormal UACR in each of the fresh
urine samples examined [4].
2.7. Praziquantel Treatment. After collection of samples at
baseline, compliant children were offered treatment with
PZQ at the standard oral dosage of 40mg/kg body weight.
The PZQ drug was procured from Pharmaceutical and
Chemical Distributors (Pvt) Ltd., Harare, Zimbabwe, a com-
pany registered and licensed to sell the antihelminthic drug
in Zimbabwe.The tablets were swallowedwith squash juice to
reduce their bitter taste and a slice of bread to reduce the side
effects of PZQ [16, 32]. For the very young children, the tablets
were crushed according to the current recommendation by
the WHO [20].
2.8. Sample Size Calculations. The relationship between
schistosomiasis infection levels and indicators of morbidity is
still unclear.We thus based our sample size calculations under
the expectations that PZQ treatment reduces reinfection rates
by more than 50% after 12 months.These expected effects are
consistent with data from previous studies [16, 25] and are
of sufficient magnitude to be of practical interest. Allowing
for dropouts, our simulation studies using StatXact v8 (Cytel
Software Corp., Cambridge, MA, USA) indicated that the
sample sizes shown in Figures 1(a) and 1(b) will give us more
than 80% power to detect age-related and treatment-related
differences with significance level, 𝛼 = 0.05.
2.9. Data Management and Statistical Analysis. Infection
intensity was log-transformed: log
10
(egg count + 1) to meet
the distributional assumptions of parametric test-statistics.
Treatment efficacy against S. haematobium infection was
assessed by means of cure rates (CR) and egg reduction rates
(ERR), defined as CR = (number of children S. haematobium
egg-negative at 12-week posttreatment/number of children
confirmed egg-positive at baseline) × 100; ERR = (arithmetic
mean egg count at baseline− arithmeticmean egg count at 12-
week posttreatment/arithmetic mean egg count at baseline)
× 100. The 95% confidence intervals (95% CI) for the ERR
were calculated using a bootstrap resampling method with
1000 replicates in R 3.1.2 (RDevelopment Core Team,Vienna,
Austria), package = “eggCounts.” A Chi-square test (𝜒2) or
Fisher’s exact test in the case of small expected frequencies
(𝑛 < 5) was used for comparison of infection prevalence and
cure rates between the two age groups. For infection intensity,
a paired 𝑡-test was used to compare levels of infection before
treatment versus after treatment. For each of the three urinary
markers of schistosome-relatedmorbidity (microhaematuria,
proteinuria, and albuminuria), the outcome of interest was a
dichotomous variable indicating whether the child presented
with morbidity or not at a given time point (morbidity: 0 =
negative; 1 = positive). The main predictor variables included
the host factors sex (male versusfemale) and age group (1–5
years versus 6–10 years), treatment group (untreated versus
PZQ treated), and time (pretreatment versus posttreatment).
To assess the effect of treatment (pre/post) on morbidity
markers, we used the method of generalized linear mixed
model (GLMM) with a random effect to account for the cor-
relation between children recruited from the same primary
school/ECD as described earlier.Themodel-building process
involved backward stepwise inclusion of the main effect
covariate terms and their two-way interactions. All statistical
analyses were performed using SAS 9.3 (SAS Institute Inc.,
Cary, NC, USA).TheGLMMswere run using “PROCGLIM-
MIX” with a logit-link function to model the log odds of the
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Table 1: Demographic characteristics of the study cohort followed up at 12-week and 12-month posttreatment with complete parasitology
data for S. haematobium infection.
Variable Characteristic Treated group Untreated controls
a
Baseline/12 weeks 12 months Baseline/12 weeks
Sample size 𝑛 303 233 61
Sex M/F 142/161 108/125 29/32
Age (years) Mean age (range) 6.6 (1–10) 6.9 (1–10) 4.9 (1–10)
Median 6 7 5
Age group, 𝑛 (%) 1–5 years 109 (36%) 80 (34%) 40 (66%)
6–10 years 194 (64%) 153 (66%) 21 (34%)
aThe data on voluntary untreated controls was only collected at baseline and 12-week follow-up surveys.
Table 2: Treatment efficacy of a single dose of praziquantel (40mg/kg) against S. haematobium infection by age group at 12-week
posttreatment. SE: standard error; CR: cure rate; ERR: egg reduction rate, with 95% confidence intervals (95% CI).
Age group Baseline (pretreatment) 12-week posttreatment Treatment efficacy
Number
(screened and
treated)
Number
(diagnosed
positive)
Mean egg
count (SE)
Number of
cases cured
Mean egg
count (SE) CR (95% CI) ERR
a (95% CI)
1–5 years 109 8 2.7 (1.79) 8 0.0 (—) 100.0% (67.7–100.0%) 100.0% (—)
6–10 years 194 84 28.8 (8.40) 79 0.6 (0.45) 94.0% (86.8–97.4%) 97.9% (89.9–99.5%)
aThe 95% confidence intervals for the ERRs were calculated using a bootstrap resampling method with 1000 replicates.
probability of a child presenting withmorbidity marker upon
examination, and the parameter estimationwas implemented
using themethod of penalized quasi-likelihood to account for
overdispersion [33]. Comparisons for the binary morbidity
marker responses between different subgroups of predictor
variables were implemented using the contrast optionswithin
the “GLIMMIX” procedure. In all the analyses, multiple pair-
wise comparisons were adjusted for familywise type I error
using the less conservative (i.e., has low rate of false negatives)
simulation-based approach [34].The level of significance was
set at𝑃 < 0.05 for all the statistical tests performed. To aid the
interpretation of the relative effect of treatment on infection
levels and morbidity markers, standard errors (SE), 95% CI,
and adjusted odds ratios (OR) were presented along with the
significance test statistics.
3. Results
3.1. Demographic Characteristics and Pretreatment Infection
Levels. Of the eligible children screened at baseline (see Fig-
ures 1(a) and 1(b)), a total of 508 childrenwere included in the
study, with 388 receiving PZQ treatment and 120 remaining
untreated. Infection prevalence in the 508 childrenwas 24.2%
(95% CI: 20.5–28.0%), 6.7% (95% CI: 3.5–9.9%) in 1–5 years
ages (𝑛 = 239), and 39.8% (95%CI: 33.9–45.7%) in 6–10 years
ages (𝑛 = 269). In a subgroup of the 508 children, serological
analysis showed that 63.0% (95% CI: 57.7–68.2%) of the
children were seropositive for S. haematobium egg antigens,
39.8% (95% CI: 33.9–45.7%) were 1–5 years (𝑛 = 131), and
79.1% (95% CI: 73.4–84.8%) were 6–10 years (𝑛 = 201). The
characteristics of the current study population are shown in
Table 1.When considering the children treated at baseline and
followed up at 12 weeks (𝑛 = 303, Figure 1(a)), the baseline
infection prevalence determined by parasitology was 30.4%
(95%CI: 25.2–35.6%) compared to 18.0% (95%CI: 8.1–28.0%)
in the children who were not treated at baseline (𝑛 = 61,
Figure 1(a)) but voluntarily remained in the study at 12 weeks.
3.2. Treatment Efficacy on Infection Levels at 12-Week Post-
treatment. Twelve weeks after treatment, PZQ was effica-
cious at reducing S. haematobium infection among treated
children in both age groups, as shown by high cure and egg
reduction rates in Table 2.The overall cure and egg reduction
rates in our study were 94.6% (95% CI: 87.9–97.7%) and
97.9% (90.6–99.5%), respectively. There was no significant
difference (Fisher’s exact test, 𝑃 = 0.481) in cure rates
between the two age groups (1–5 years versus 6–10 years) 12
weeks after treatment shown in Table 2.
3.3. Effect of Treatment on Infection/Reinfection Rates at 12-
Month Posttreatment. Following initial treatment at baseline,
children who had successful curative treatment were further
followed up to determine the reinfection rates and proportion
of new infections 12 months after intervention. Table 3 shows
the percentage proportion of treated children who were
infected at baseline and then got reinfected (𝑛 = 7) and those
newly infected (𝑛 = 11) within 12 months following treat-
ment.The infection prevalence 12months after treatment was
low (i.e.,<10% according toWHOclassifications) as shown in
Table 3. Furthermore, the proportion of infected/reinfected
children did not significantly differ (𝜒2 = 0.37; 𝑃 = 0.542)
between the two age groups: 1–5 years, 𝑛 = 5: 6.3% (95%
CI = 2.7–13.8%) versus 6–10 years, 𝑛 = 13: 8.5% (95% CI:
4.8–14.4%). Similarly, the mean infection intensity level 12
months after treatment (mean = 0.74 egg/10mL urine; SE =
0.27)was significantly lower (paired 𝑡-test =−7.95;𝑃 < 0.001)
compared to the baseline level (mean = 14.3 egg/10mL urine;
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Table 3: Levels of S. haematobium reinfection and new infection rates among treated children in the study 12 months following treatment
with single dose of 40mg/kg praziquantel. Percentage proportions, with 95% confidence intervals (95% CI) of children infected with S.
haematobium detected by parasitology.
Infection group Sample size (𝑛)
12-month posttreatment S. haematobium
infection/reinfection rate
Number (egg-positive) Prevalence (95% CI)
Reinfectionsa 76 7 9.2% (4.5–17.8%)
New infectionsb 157 11 7.0% (4.0–12.1%)
aEgg-positive at baseline and reinfected 12 months after treatment.
bUninfected at baseline and found egg-positive 12 months after treatment.
SE = 4.63) in this study, with all egg-positive children carrying
light infection intensities only.
3.4. Effect of Treatment on Morbidity Markers at 12-Week
Posttreatment. The effect of PZQ on levels of morbidity
markers was assessed in those children that had successfully
cleared the infection at 12 weeks. Praziquantel significantly
reduced levels of proteinuria and albuminuria 12 weeks after
treatment (Figure 2). In addition, the odds of children who
received praziquantel presenting with each of these markers
of morbidity 12 weeks after treatment were lower compared
to the odds before treatment, adjusting for sex and age
group: proteinuria: OR = 0.54; (95% CI: 0.31–0.95) and
albuminuria: OR = 0.05; (95% CI: 0.02–0.14). Furthermore,
all the treated children aged 1–5 years successfully cleared
albuminuria at 12 weeks and a significant reduction from
baseline was observed among the 6–10 years ages (Figure 2).
A mild decrease in the levels of microhaematuria among the
treated preschool-aged children was also observed; however,
these changes were not significant. Changes from baseline
in the levels of the three markers of schistosome-related
morbidity in untreated children at 12 weeks were not signif-
icant (Figure 2). Furthermore, when evaluating the overall
changes in morbidity markers among the treated group (pre-
versusposttreatment) compared to the changes in untreated
children, it was observed that the odds of albuminuria were
lower, OR = 0.43 (95% CI: 0.19–0.98; 𝑃 = 0.045), adjusting
for sex and age group.
3.5. Effect of Treatment on Morbidity Markers at 12-Month
Posttreatment. Following curative treatment of infection at
12 weeks, as assessed by parasitology, children were further
followed up and examined for morbidity at 12 months.
Our analyses showed that when morbidity marker levels
were investigated relative to baseline levels, microhaematuria
significantly dropped in both age groups at 12 months after
treatment (Figure 3). Furthermore, the results of GLMMs
weighted by age group sample sizes showed that the odds of
treated children presenting with microhaematuria 12 months
after treatment did not significantly differ between children
of 1–5 years and6–10 years: OR = 0.97; (95% CI: 0.50–1.87). In
the case of proteinuria and albuminuria at 12 months, there
was a significant reduction relative to baseline in the older age
group, but not in 1–5 year ages (Figure 3). This was despite
the initial reduction in albuminuria levels in this age group
observed 12 weeks after treatment, as was shown in Figure 2.
4. Discussion
Praziquantel is currently the recommended antihelminthic
drug of choice by the WHO for treating schistosomiasis
and is effective against all the major schistosome species
infecting humans [9]. As of present, the health benefits of
PZQ treatment in children aged 5 years and below have not
yet been extensively evaluated. Thus, in this study we sought
to determine if PZQ treatment improves the current health
status of children aged 1–5 years. The pretreatment infection
levels reported in this study confirmed that preschool-aged
children are exposed to schistosome infection, in concur-
rence with findings from other recent studies [16, 30], and
further support the premise that if left untreated, these chil-
dren are at an increased risk of developing severe morbidity
that may cause serious health consequences and negatively
impact their future quality of life [18, 35, 36]. In this study
there were few children aged between 1 and 5 years who were
excreting parasite eggs, but the prevalence of 6.7% is typical
in this age group. More importantly, we and others [17, 30]
have shown that the widely utilized egg count diagnostic
method greatly underestimates infection prevalence in young
children. Indeed, in a seroprevalence study of a subgroup
of the 508 children in this group, the seropositive rate for
S. haematobium egg antigen was 39.8% in 1–5 years ages.
Thus, it is important to investigate the effects of treatment on
othermarkers with health implications other than just the egg
counts.
Our study results at 12 weeks after chemotherapy showed
that a single standard dosage of PZQwas efficacious against S.
haematobium infection in both 1–5 years and 6–10 years ages.
The ranges of cure and egg reduction rates observed in this
study for both age groups are consistent with data reported
in the literature that have also shown high PZQ treatment
efficacy within six weeks after treatment [16, 37, 38]. More
interestingly, our study further revealed that PZQ treatment
was effective in reducing S. haematobium infection levels in
preschool-aged children as was observed in their older coun-
terparts (6–10 years ages), further supporting their inclusion
in current schistosomiasis control programmes [20, 39].
Infection prevalence remained lower 12 months after
treatment compared to baseline levels, and the proportion
of infected/reinfected children did not significantly differ
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Figure 2: Effect of praziquantel (PZQ) treatment on the levels of urinary markers of schistosome-related morbidity 12 weeks after treatment.
(a) Microhaematuria, (b) proteinuria, and (c) albuminuria. The error bars indicate the 95% confidence intervals. The 𝑃 values for pairwise
comparisons are from generalized linear mixed models investigating the probability of a child presenting with morbidity marker pre- versus
posttreatment adjusted for sex and age group. Significant 𝑃 values are marked with †. ∗Contrast 𝑃 value determined using the Binomial exact
test.
between the two age groups. In addition, our study showed
significant reductions in mean S. haematobium egg counts 12
months after treatment compared to baseline. These results
are in agreement with those of previous studies fromdifferent
endemic areas that also reported a lower risk of S. haema-
tobium reinfection after annual school-based treatment [40,
41], indicative of the benefit of treatment in the prevention
of infection through reduced parasite transmission at popu-
lation level [40].This combination of findings on the benefits
of PZQ chemotherapy against infection provides some strong
support for the need for inclusion of preschool-aged children
in ongoing schistosomiasis control programmes, in order to
increase the effectiveness of coverage of those infected, also
recently highlighted in a study by Garba et al. [1].
Since schistosome-related morbidity is cumulative and
progressive [42], decrease in current morbidity can reduce
the long-term schistosomiasis sequelae. At 12 weeks after
the first treatment, there was a significant decrease in the
levels of the morbidity markers proteinuria and albuminuria
in children successfully treated for infection. Interestingly,
the effects of treatment were found not to be age-related,
with microalbuminuria completely reversed in preschool-
aged children at 12 weeks. The study also revealed that
the prevalence of morbidity, diagnosed by presence micro-
haematuria, declined slowly, with a significant reduction
observed after 12-month posttreatment. Our findings on the
immediate health benefits of PZQ treatment were further
reinforced by the results of the untreated group, showing no
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Figure 3: Effect of praziquantel treatment on levels of urinary markers of schistosome-related morbidity 12 months after treatment. (a)
Microhaematuria, (b) proteinuria, and (c) albuminuria. Error bars indicate 95% CI and the 𝑃 values for pairwise comparisons are from
the generalized linear mixed models investigating the probability of a child presenting with morbidity markers before and after treatment,
adjusted for sex and age group. Significant 𝑃 values are marked with †.
significant change in the levels of markers of schistosome-
related morbidity at the 12-week follow-up.
The results showing persistently high levels of micro-
haematuria 12 weeks after treatment differ from some pub-
lished studies that reported a considerable drop in micro-
haematuria within eight weeks after PZQ treatment [5, 43,
44]. However, most of these studies focused on older school-
aged children who may have developed chronic infection.
The high sensitivity of dipstick reagent strips in detecting
microhaematuria, as previously reported [45], could also be
one possible reason for these findings in our study. Another
possible explanation for this delayed decrease in micro-
haematuria may be that most of the observed microhaema-
turia in these children may have likely been due to other
health conditions other than schistosome infection. In an
earlier study of this populationwe showed that the proportion
ofmicrohaematuria attributable to schistosome infectionwas
less than that of albuminuria and proteinuria [22]. These
results therefore need to be interpreted with caution.
One of the main objectives of schistosomiasis control
programmes in endemic areas is preventative chemother-
apy to combat the development of severe morbidity [20].
Thus, more efforts are needed to ensure that the imme-
diate health benefits of chemotherapy are sustained in the
targeted populations for effective control [1]. The current
study revealed that a single PZQ treatment had sustained
effects on the reduction of schistosome-related morbidity,
as indicated by the levels of urinary markers that remained
low 12 months after treatment. Furthermore, it is interesting
to note that both the preschool and primary-school age
groups demonstrated improved health beneficial treatment
effect in terms of reduced morbidity burden measured
by microhaematuria 12 months following single treatment
with PZQ. In view of the current observations showing no
BioMed Research International 9
age-related differences in treatment efficacy, it is thus prac-
tically possible for control programmes in endemic areas
targeting preschool-aged children to be implemented using
the existing treatment strategies designated for school-aged
children.
Nevertheless, our study has limitations that must be con-
sidered when interpreting these results. Firstly, participation
of the controls was on a voluntary basis for ethical reasons,
hence leading to a small sample size for this group. This
could have introduced additional uncertainties in the levels of
infection and schistosome-relatedmorbiditymarkers leading
to a potential bias in the effects of treatment reported in this
study. Tominimise the effects of this potential bias, a random
effect was included in the statistical models to account for
some of the uncertainty. Secondly, since the majority of the
children carried light infections, the parasitological cure rates
may have been overestimated. Nonetheless, it is reassuring
that efficacy rates reported in our studywere comparable with
those observed from other previous epidemiological studies
in the same age range [1, 16].
5. Conclusions
In this study, we have demonstrated that praziquantel treat-
ment effectively reduces not only S. haematobium infec-
tion levels, but also the levels of related morbidity in
both preschool and primary school-aged children, with the
reduction in some morbidity markers recorded within 12
weeks of treatment being sustained over a period of one
year. In conclusion, praziquantel treatment has immediate
health benefits in preschool-aged children exposed to S.
haematobium, and the effect of praziquantel on infection and
morbidity measures is not age-dependent. These findings are
important for practitioners, policy makers, and stakeholders
involved in the control of schistosomiasis and timely because
of the current global drive to address the health iniquity
created by the paucity of information on the impact of
praziquantel treatment on schistosome-related morbidity in
children aged 5 years and below.
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